BRD2 and ovarian carcinoma: Previous research demonstrated that follicle-stimulating hormone (FSH)-enhanced glycolysis in ovarian cancer contained a high level of ACTL6A and that ACTL6A increased phosphoglycerate kinase 1 (PGK1), therefore aiding the proliferation of ovarian cancer [22].